Key result
CKD alters HDL composition and impairs cholesterol efflux capacity without predicting cardiovascular events.
Why the study?
In patients with chronic kidney disease, neither serum HDL cholesterol levels nor cholesterol efflux capacity associate with cardiovascular events despite a high cardiovascular burden, and impaired renal function directly alters HDL metabolism, composition, and functionality.
Investigating the functional and compositional features of HDL subclasses, rather than just HDL cholesterol levels, may be necessary to understand the link between HDL and cardiovascular disease in patients with chronic kidney disease.
Answers are grounded in this paper and cite their sources.
HDL remodeling and efflux impairment in CKD lack event prediction; leaves open whether subclass-specific composition clarifies risk.
In the general population, the ability of high-density lipoproteins (HDLs) to promote cholesterol efflux is a predictor of cardiovascular events, independently of HDL cholesterol levels. Although patients with chronic kidney disease (CKD) have a high burden of cardiovascular morbidity and mortality, neither serum levels of HDL cholesterol, nor cholesterol efflux capacity associate with cardiovascular events. Important for the following discussion on the role of HDL in CKD is the notion that traditional atherosclerotic cardiovascular risk factors only partially account for this increased incidence of cardiovascular disease in CKD. As a potential explanation, across the spectrum of cardiovascular disease, the relative contribution of atherosclerotic cardiovascular disease becomes less important with advanced CKD. Impaired renal function directly affects the metabolism, composition and functionality of HDL particles. HDLs themselves are a heterogeneous population of particles with distinct sizes and protein composition, all of them affecting the functionality of HDL. Therefore, a more specific approach investigating the functional and compositional features of HDL subclasses might be a valuable strategy to decipher the potential link between HDL, cardiovascular disease and CKD. This review summarizes the current understanding of the relationship of HDL composition, metabolism and function to their cardio-protective properties in CKD, with a focus on CKD-induced changes in the HDL proteome and reverse cholesterol transport capacity. We also will highlight the gaps in the current knowledge regarding important aspects of HDL biology.
No takes yet. Share an insight, caveat, or question.
Marsche et al. (2020) conducted a review in Chronic kidney disease and cardiovascular disease. HDL composition, structure, and function (including cholesterol efflux capacity) vs. General population / healthy controls with intact renal function was evaluated on Cardiovascular events and mortality in chronic kidney disease. Chronic kidney disease induces significant HDL remodeling (enriched SAA1 and apoC-III, reduced apoA-I and PON1) and impairs cholesterol efflux capacity, though neither predicts cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: